Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Aug 13, 2024

SELL
$16.88 - $23.31 $5,064 - $6,993
-300 Closed
0 $0
Q4 2020

Aug 13, 2024

BUY
$4.01 - $7.58 $1,203 - $2,274
300 New
300 $1.62 Million
Q1 2019

Aug 13, 2024

BUY
$1.68 - $3.42 $504 - $1,026
300 New
300 $915,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $653M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.